Integral Diagnostics Ltd (IDX) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Integral Diagnostics Ltd stock A$1.39, price A$1.72, that is 19.4% below the price, quality 33 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range A$1.56 – A$4.72 · fair‑value band A$1.11 – A$1.80 · the A$1.72 price screens above the A$1.39 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Integral Diagnostics in your weekly email
Every Wednesday you see whether Integral Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand.
Show moreShow less
The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia.
Stock analysis
Integral Diagnostics Ltd (IDX) currently trades at A$1.72, while our model-based Fair Value estimate is A$1.39, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of A$3.77 per share, and 12 of the 24 models we run sit above the A$1.72 price.
Bear case: the Economic Profit group reads lowest at A$1.06, and 12 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: A$1.11 (bear) to A$1.80 (bull), the price of A$1.72 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Integral Diagnostics Ltd reported revenue of A$789M in FY2026 versus A$359M in FY2022, a compound +21.8%/yr. Reported net income was A$21.9M in FY2026, compounding +10.7%/yr from FY2022.
Key figures
Market cap A$658M (≈ $454M) Small · P/E ratio 28.7 · P/S ratio 0.84 · EPS (TTM) A$0.0600 · Dividend yield 5.4% · Net margin 2.8% · Return on equity 3.2% · Return on assets (EBIT) 4.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −19%, IDX screens richer than that median.
Fair Value models
BearA$1.11Fair Value A$1.39BullA$1.80
Price A$1.72 · Downside -19.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual IncomeA$1.31A$1.29A$1.3176
FCF DCFA$2.11A$3.98A$9.1174
EPVA$0.6100A$0.8200A$1.0174
All 24 models by family
DCF Models
FCF DCFA$2.11A$3.98A$9.1174
Owner EarningsA$1.81A$4.90A$11.0569
5Y Revenue ExitA$1.29A$2.90A$5.9567
5Y EBITDA ExitA$2.81A$6.20A$12.2970
5Y P/E ExitA$0.7400A$1.90A$3.3167
10Y Revenue ExitA$1.47A$3.47A$5.8464
10Y EBITDA ExitA$2.57A$6.24A$12.9363
10Y P/E ExitA$1.16A$2.47A$4.5560
Earnings-Based
Graham-DoddA$0.4000A$2.76A$3.8863
Lynch FVA$0.8100A$1.16A$1.5161
PEG = 1.0A$0.8100A$1.16A$1.5157
EPVA$0.6100A$0.8200A$1.0174
Dividend Discount
Gordon GGMA$0.6000A$1.19A$1.7867
DDM Multi-StageA$0.6000A$1.03A$1.2667
Multiples
P/E MultipleA$0.9700A$1.29A$1.6163
P/S MultipleA$0.7500A$1.00A$1.2558
EV/EBITA$0.8500A$1.62A$2.3963
EV/EBITDAA$2.53A$3.86A$5.1966
EV/RevenueA$0.1900A$0.8900A$1.6048
Growth DCF
Growth DCFA$1.98A$4.43A$8.8773
Rev-Margin DCFA$1.29A$3.10A$5.7868
Economic Profit
Residual IncomeA$1.31A$1.29A$1.3176
ROIC CompounderA$0.6100A$0.8200A$1.0172
Growth Earnings
Growth-Adj P/EA$1.14A$1.63A$2.1267
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+25.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Start year 2021 (pandemic). Over 10 years: +16.7% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−7.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.6%
Dividend (yield on the price)5.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.6% vs −3.4%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +6.7% a year for the price and +2.2% for the forecasts.
Compare Integral Diagnostics Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−19.4% · Above median
Profitability
Return on equity (12 months)3.2% · Below median
Return on assets1.5% · Below median
Net margin (12 months)2.8% · Below median
Operating margin (12 months)10.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)5.6% · Below median
Dividend yield (12 months)5.4% · Top 25%
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (12 months)28.7× · Cheaper than median
P/B0.97× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Integral Diagnostics Ltd (IDX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of A$1.39 versus a price of A$1.72, about 19% lower (overvalued).
What is the fair value of IDX?
Our model-based fair value for Integral Diagnostics Ltd is A$1.39 (as of Nov 6, 2026), built from audited fundamentals. The current price: A$1.72.
What is the quality score of IDX?
Integral Diagnostics Ltd has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integral Diagnostics Ltd (IDX)?
Our model-based price target is the fair value of A$1.39 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario A$1.11, optimistic scenario A$1.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Integral Diagnostics Ltd stock forecast for 2026?
Our models put fair value at A$1.39, about 19% lower versus a price of A$1.72 (overvalued). Cautious scenario A$1.11, optimistic scenario A$1.80. The calculation is refreshed regularly with new filings.
What is the revenue of Integral Diagnostics Ltd (IDX)?
Integral Diagnostics Ltd reported trailing-twelve-month revenue of about A$789M (latest available figure, as of Nov 6, 2026).
Does Integral Diagnostics Ltd pay a dividend?
Integral Diagnostics Ltd currently shows a dividend yield of 5.41% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Integral Diagnostics Ltd (IDX) and when is the ex-dividend date?
Integral Diagnostics Ltd pays a dividend of A$0.093 per share a year, a dividend yield of 5.4%. The last ex-dividend date was Aug 28, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 155% of earnings. Free cash flow covers the dividend 1.31 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Integral Diagnostics Ltd (IDX)?
For today's price to be fair in a discounted-cash-flow model, Integral Diagnostics Ltd would have to grow free cash flow by +9.9 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.7 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of IDX use?
Our models discount Integral Diagnostics Ltd at 9.6 %: a base by market capitalisation (small), damped by beta 0.18, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Integral Diagnostics Ltd that is +9.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Integral Diagnostics Ltd (IDX) delivered so far?
Over the past 5 years revenue at Integral Diagnostics Ltd grew +17.7 % a year. The price currently implies free-cash-flow growth of +9.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Integral Diagnostics Ltd (IDX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Integral Diagnostics Ltd (+9.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Integral Diagnostics Ltd (IDX)?
The free-cash-flow yield on the price is 7.03 %: that much free cash flow Integral Diagnostics Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Integral Diagnostics Ltd (IDX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integral Diagnostics Ltd it is A$1.39 per share (as of Nov 6, 2026), against a price of A$1.72. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Integral Diagnostics Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, IDX trades above its calculated fair value: price A$1.72, fair value A$1.39, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDX?
No. The price is what the market pays today (A$1.72); the fair value is what the company's own numbers justify (A$1.39). For Integral Diagnostics Ltd the two are A$0.3345 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integral Diagnostics Ltd worth?
The market values Integral Diagnostics Ltd at about A$658M (market capitalisation, as of Nov 6, 2026). Per share that is A$1.72; our models calculate a fair value of A$1.39 per share.
What do the bullish and bearish scenarios say about IDX?
Our models span a range for Integral Diagnostics Ltd: cautious scenario A$1.11, base A$1.39, optimistic A$1.80 per share (as of Nov 6, 2026, price A$1.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IDX?
Integral Diagnostics Ltd trades at a price-to-earnings ratio of 28.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$1.39 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2026), reported earnings: 33.0. Other multiples: P/B 1.0, P/S 0.8, EV/EBITDA 8.4.
How solid is the balance sheet of Integral Diagnostics Ltd (IDX)?
Balance-sheet figures for Integral Diagnostics Ltd (as of Nov 6, 2026): return on equity 3.2%, debt of 0.51 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is IDX from its 52-week high?
Integral Diagnostics Ltd trades at A$1.72, about 35% below its 52-week high of A$2.64 and 1% above the low of A$1.71 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$1.39 is for.
Which stocks are comparable to Integral Diagnostics Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integral Diagnostics Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price A$1.72, calculated fair value A$1.39 (−19%), Quality Score 33/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDX calculated?
We run Integral Diagnostics Ltd through 24 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of A$1.39 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Integral Diagnostics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integral Diagnostics Ltd (IDX)?
The closing price on Nov 9, 2026 was A$1.72. Our model-based fair value is A$1.39, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integral Diagnostics Ltd right now?
Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Integral Diagnostics Ltd (IDX) come from?
Earnings per share at Integral Diagnostics Ltd grew −7.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +5.5 %, EBIT margin −5.5 %, tax rate −0.6 %, residual (interest, one-offs) −6.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Integral Diagnostics Ltd
How large is the market capitalisation of Integral Diagnostics Ltd (IDX)?
The market capitalisation of Integral Diagnostics Ltd is A$658M (≈ $454M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integral Diagnostics Ltd (IDX)?
The price-to-sales ratio of Integral Diagnostics Ltd is 0.84 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integral Diagnostics Ltd (IDX)?
Earnings per share at Integral Diagnostics Ltd are A$0.0600 (price ÷ EPS = P/E 28.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Integral Diagnostics Ltd (IDX)?
The dividend yield of Integral Diagnostics Ltd is 5.4% (payout 155%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Integral Diagnostics Ltd (IDX)?
The net margin of Integral Diagnostics Ltd is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integral Diagnostics Ltd (IDX)?
The return on equity (ROE) of Integral Diagnostics Ltd is 3.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integral Diagnostics Ltd (IDX)?
On an EBIT basis the return on assets of Integral Diagnostics Ltd is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Integral Diagnostics Ltd (IDX)?
The operating margin of Integral Diagnostics Ltd is 10.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Integral Diagnostics Ltd (IDX)?
Revenue at Integral Diagnostics Ltd is growing +5.6% versus a year earlier (3y avg +21.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integral Diagnostics Ltd (IDX)?
Earnings per share at Integral Diagnostics Ltd are growing +304% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Integral Diagnostics Ltd (IDX) carry?
The net debt of Integral Diagnostics Ltd is A$546M (fiscal year 2026, ≈ 12.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Integral Diagnostics Ltd in the live analysis
One click puts Integral Diagnostics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026